ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.07 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.67, a 29.29% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.19.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $3.48, a 48.82% decline year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $6.80, a 34.39% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.98, a 72.53% decline from fiscal 2024.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $18.13, a 164.67% increase from fiscal 2023.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.85, a 172.91% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.51, a 58.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.07 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $3.67 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $4.98 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $4.98 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $4.98 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $5.19 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $18.13 10-K · filed 2025-03-10 | |||
| 2023-12-31 | $6.85 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $6.88 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $6.83 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.48 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $2.51 10-K · filed 2023-03-27 | |||
| 2022-09-30 | $4.36 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $4.84 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $6.80 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $6.03 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $5.59 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $5.42 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $5.06 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |